CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

British Journal of Cancer

Volumn 101, Issue 11, 2009, Pages 1817-1823

  Jernstrom H ^a,b   Bgeman, E ^a   Rose, C ^c   Jonsson P E ^c,d   Ingvar, C ^c  

^a LUND UNIVERSITY   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d HELSINGBORG HOSPITAL   (Sweden)

Author keywords

CYP2C8; CYP2C9; Disease free survival; Polymorphism; Tamoxifen

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 2C9;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST TUMOR; CANCER PATIENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN POLYMORPHISM; QUESTIONNAIRE; SWEDEN;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HAPLOTYPES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 70549085147     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605428     Document Type: Article

References (31)

1. Arisio R, Sapino A, Cassoni P, Accinelli G, Cuccorese MC, Mano MP, Bussolati G (2000) What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas J Clin Pathol 53:846-850
2. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579-1589
3. Belton O, Fitzgerald DJ (2003) Cyclooxygenase isoforms and atherosclerosis. Expert Rev Mol Med 5:1-18
4. Boruban MC, Yasar U, Babaoglu MO, Sencan O, Bozkurt A (2006) Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother 18:421-424
5. Chebil G, Bendahl PO, Ferno M (2003) Estrogen and progesterone receptor assay in paraffin-embedded breast cancer-reproducibility of assessment. Acta Oncol 42:43-47
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607
7. Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, Ferno M (2008) Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 109:255-262
8. Dorado P, Cavaco I, Caceres MC, Piedade R, Ribeiro V, Llerena A (2008) Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol 64:967-970
9. Early breast cancer trialists' collaborative group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials. Lancet 365:1687-1717
10. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up. Histopathology 19:403-410
11. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial. Lancet Oncol 9:45-53
12. Glass AG, Lacey Jr JV, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980-2006:combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99:1152-1161
13. Goetz MP, Kamal A, Ames MM (2008) Tamoxifen pharmacogenomics:the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83:160-166
14. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2007) Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144
15. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl ML (2003) Bioactivation of cyclophosphamide:the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 59:103-109 (Pubitemid 36793721)
16. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies:pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526
17. Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, Card JW, Wang J, Zeldin DC, Wang DW (2007) Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Res 67:6665-6674
18. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
19. King BP, Khan TI, Aithal GP, Kamali F, Daly AK (2004) Upstream and coding region CYP2C9 polymorphisms:correlation with warfarin dose and metabolism. Pharmacogenetics 14:813-822
20. Malmström P, Bendahl PO, Boiesen P, Brünner N, Idvall I, Fernö M, South Sweden Breast Cancer Group (2001) S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19:2010-2019
21. Malmström P, Holmberg L, Anderson H, Mattsson J, Jönsson PE, Tennvall-Nittby L, Balldin G, Loven L, Svensson JH, Ingvar C, Möller T, Holmberg E, Wallgren A, Swedish Breast Cancer Group (2003) Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer:a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer 39:1690-1697
22. Medhora M, Daniels J, Mundey K, Fisslthaler B, Busse R, Jacobs ER, Harder DR (2003) Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 284:H215-H224
23. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R (2005) Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 118:5489-5498
24. Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, Busse R (2003) Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 17:770-772
25. NCBI SNP homepage (2008) NCBI SNP homepage Access date 2008-07-15 http://www.ncbi.nlm.nih.gov/SNP/snp-ref.cgirs 1058930
26. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E (2004) The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32:484-489
27. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193
28. Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68-78
29. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping:frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-631
30. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299:25-28
31. Zeldin DC, DuBois RN, Falck JR, Capdevila JH (1995) Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 322:76-86